Pharmaceutical Information |
Drug Name |
Abarelix |
Drug ID |
BADD_D00011 |
Description |
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. |
Indications and Usage |
For palliative treatment of advanced prostate cancer. |
Marketing Status |
Discontinued |
ATC Code |
L02BX01 |
DrugBank ID |
DB00106
|
KEGG ID |
D02738
|
MeSH ID |
C423508
|
PubChem ID |
16131215
|
TTD Drug ID |
D01AHO
|
NDC Product Code |
Not Available |
Synonyms |
abarelix | Plenaxis | PPI-149 |
|
Chemical Information |
Molecular Formula |
C72H95ClN14O14 |
CAS Registry Number |
183552-38-7 |
SMILES |
CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(
CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=
O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|